LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

Strona główna・Stock List・Ascendis Pharma A-S ADR

Ascendis Pharma A-S ADR

Open

SectorHealthcare

225.18 -0.39

Buy Sell

Overview

Share price change

24h

Current

Min

225.12

Max

226.94

Key metrics
By Trading Economics
Income	28M -33M
Sales	32M 245M
Profit margin	-13.56
Employees	1,189
EBITDA	68M 15M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+29.8% upside

Dividends
By Dow Jones
Next Earnings	30 kwi 2026

Market Stats
By TradingEconomics
Market Cap	1.2B 15B
Previous open	225.57
Previous close	225.18

News Sentiment

By Acuity

54%

46%

274 / 351 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

157.66 / 167.29 Support & Resistance

Ascendis Pharma A-S ADR Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

15 mar 2026, 21:14 UTC

Major News Events

Week Ahead for FX, Bonds: Central Bank Decisions -2-

15 mar 2026, 21:14 UTC

Major News Events

Week Ahead for FX, Bonds: Central Bank Decisions in Focus After Jump in Energy Prices

16 mar 2026, 00:00 UTC

Major News Events

Hack on U.S. Medical Company Shows Reach of Iran's Cyber Capabilities -- WSJ

15 mar 2026, 23:45 UTC

Market Talk

Nikkei May Decline on Concerns About Prolonged Middle East Conflict -- Market Talk

15 mar 2026, 23:44 UTC

Market Talk

Major News Events

Gold Falls as Rising Energy Prices Exacerbate Inflation Worries -- Market Talk

15 mar 2026, 23:35 UTC

Market Talk

Major News Events

Oil Futures Rise on Supply Disruption Concerns -- Market Talk

15 mar 2026, 23:00 UTC

Acquisitions, Mergers, Takeovers

Micron Completes Acquisition Of PSMC's Tongluo P5 Site In Taiwan >MU

15 mar 2026, 22:37 UTC

Market Talk

March Rate Hike Would Distance RBA From Government's May Budget -- Market Talk

15 mar 2026, 22:18 UTC

Market Talk

RBA's Likely Hike Motivated By Inflation, Not Middle East -- Market Talk

15 mar 2026, 22:14 UTC

Earnings

Genscript Biotech 2025 Adj Net $230.35M Vs. Adj Net $59.83M>1548.HK

15 mar 2026, 22:14 UTC

Earnings

Genscript Biotech: 2025 Loss Due to High Base Effect, One-off Unrealized Gains Seen Last Year >1548.HK

15 mar 2026, 22:14 UTC

Earnings

Genscript Biotech 2025 Rev $959.53M Vs. $594.49M >1548.HK

15 mar 2026, 22:14 UTC

Earnings

Genscript Biotech 2025 Loss $532.83M Vs. Net $2.96B >1548.HK

15 mar 2026, 22:14 UTC

Earnings

Genscript Biotech: 2025 Rev Supported by Substantial Increase in License Revenue>1548.HK

15 mar 2026, 22:00 UTC

Major News Events

Oil Industry Warns Trump Administration Energy Crisis Will Likely Worsen -- WSJ

15 mar 2026, 22:00 UTC

Major News Events

Oil Industry Warns Trump Administration Energy Crisis Will Likely Worsen -- WSJ

15 mar 2026, 03:00 UTC

Major News Events

For Xi, Iran War Reinforces View of U.S. as Dangerous Superpower -- WSJ

14 mar 2026, 15:00 UTC

Major News Events

Iran War Delivers Windfall to America's Oil Country -- WSJ

14 mar 2026, 02:03 UTC

Earnings

This Copper Stock Is Worth Mining for Profits -- Barrons.com

14 mar 2026, 01:32 UTC

Acquisitions, Mergers, Takeovers

Bill Ackman's Pershing Square IPO Is Back On -- Barrons.com

14 mar 2026, 00:29 UTC

Acquisitions, Mergers, Takeovers

13D Filings -- Barrons.com

13 mar 2026, 22:27 UTC

Market Talk

Major News Events

Bahrain Faces Uncertainty But Has Support Amid War, S&P Says -- Market Talk

13 mar 2026, 22:13 UTC

Market Talk

Major News Events

Saudi Arabia Seen as Able to Weather Iran Conflict, S&P Says -- Market Talk

13 mar 2026, 22:04 UTC

Market Talk

Major News Events

Emirate of RAK Outlook Stable Despite Iran War, S&P Says -- Market Talk

13 mar 2026, 22:00 UTC

Acquisitions, Mergers, Takeovers

Trump Administration Set to Receive $10 Billion Fee for Brokering TikTok Deal -- WSJ

13 mar 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

13 mar 2026, 20:50 UTC

Market Talk

Major News Events

Financial Services Roundup: Market Talk

13 mar 2026, 20:02 UTC

Market Talk

Canada Rate Hike in 2026 Would Mark 'Extraordinarily Bad' Policy -- Market Talk

13 mar 2026, 19:50 UTC

Market Talk

Major News Events

Oil Posts Weekly Gains As Middle East Conflict Drags On -- Market Talk

13 mar 2026, 19:35 UTC

Major News Events

Oil Prices Hover Near $100. India Asks Iran to Allow 23 Tankers Through Strait of Hormuz. -- Barrons.com

Peer Comparison

Price change

Ascendis Pharma A-S ADR Forecast

Price Target

By TipRanks

29.8% upside

12 Months Forecast

Average 293.33 USD 29.8%

High 342 USD

Low 255 USD

Based on 12 Wall Street analysts offering 12 month price targets forAscendis Pharma A-S ADR - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

12 ratings

Buy

Hold

Sell

Based on 12 analysts giving stock ratings to Ascendis Pharma A-S ADR - Dist in the past 3 months.

Technical Score

By Trading Central

157.66 / 167.29Support & Resistance

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

All events are bullish.

Sentiment

By Acuity

274 / 351 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Ascendis Pharma A-S ADR

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.